Get featured on Genomics Media Outlets in 48 hours

Yes, a founder can do their own PR, but it's a significant time commitment with a steep learning curve. The process involves building media lists, crafting personalized pitches for hundreds of journalists, and relentless follow-up. For highly technical fields like genomics, it's challenging to get a journalist's attention without an existing relationship. While DIY is free, the opportunity cost is high. Using a distribution service automates the submission process, guaranteeing your news reaches hundreds of outlets. This frees you up to focus on the science and business, while still securing the media placements you need for credibility and SEO.

The cost varies dramatically based on the approach. Hiring a traditional PR agency is the most expensive option, typically involving retainers of $5,000 to $15,000 per month. Doing it yourself is technically free, but the time investment required to pitch journalists and manage follow-ups is substantial. Press release distribution services offer a more predictable, one-time cost. Instead of a monthly retainer, you pay per campaign for guaranteed placement on a set number of news sites and directories. This model provides clear deliverables for a fixed price. You can see our current package pricing for specific numbers.

Once your press release is written and approved, the distribution process is very fast. After you submit your release through our platform, it undergoes a quick editorial review to ensure it meets publisher guidelines. Following approval, publication on our network of media outlets like MarketWatch and Benzinga typically begins within 24 to 48 hours. You will receive a full PDF report with live links to all your placements within 3 business days, allowing you to quickly leverage the coverage.

Announcements tied to verifiable, external validation perform best. For genomics, this includes securing a significant funding round (Series A and beyond), publishing research in a respected peer-reviewed journal, receiving FDA clearance or other key regulatory approvals, and announcing a partnership with a major pharmaceutical company or research institution. General company news like a website redesign or hiring a junior team member won't get traction. The news must be substantial and signal meaningful progress. Focus on milestones that prove your science is advancing and your business is growing.

Editors reject releases that read like advertisements or lack a genuine news hook. To avoid this, write in a neutral, third-person tone. Your headline must state the news factually, not make a marketing claim. For example, use "Announces $10M Series A" instead of "Revolutionizes Genomic Data Analysis." Avoid excessive jargon, superlatives like "game-changing" or "world's first," and exclamation points. Every claim should be attributable and factual. Our AI-powered editor helps you format your release to meet these journalistic standards, significantly reducing the risk of rejection by our network partners.

Yes, it's a critical part of their due diligence process. When investors or potential pharma partners evaluate your company, they will search for you online. Finding a consistent trail of press releases on credible sites like Yahoo Finance, AP News, and Business Insider validates your milestones and builds confidence. This coverage acts as a third-party endorsement of your progress. It shows you are achieving the goals you set out to accomplish, whether it's securing funding, publishing data, or gaining regulatory approval. It's not just about the article; it's about creating a public record of credibility and momentum.